scPharmaceuticals (NASDAQ:SCPH) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a research report released on Thursday,Benzinga reports. They currently have a $18.00 target price on the stock.

scPharmaceuticals Stock Performance

Shares of SCPH stock opened at $3.01 on Thursday. scPharmaceuticals has a 12 month low of $2.75 and a 12 month high of $5.70. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The firm has a market capitalization of $150.62 million, a P/E ratio of -1.58 and a beta of 0.40. The company’s fifty day moving average price is $3.28 and its two-hundred day moving average price is $3.80.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The firm had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.08 million. On average, research analysts anticipate that scPharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On scPharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC bought a new stake in shares of scPharmaceuticals in the 3rd quarter worth about $9,343,000. Rubric Capital Management LP increased its position in shares of scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after purchasing an additional 1,250,000 shares during the last quarter. King Luther Capital Management Corp increased its position in shares of scPharmaceuticals by 28.4% in the 4th quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock worth $10,117,000 after purchasing an additional 632,120 shares during the last quarter. Rice Hall James & Associates LLC increased its position in shares of scPharmaceuticals by 59.2% in the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock worth $3,503,000 after purchasing an additional 367,970 shares during the last quarter. Finally, Stonepine Capital Management LLC increased its position in shares of scPharmaceuticals by 84.7% in the 3rd quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock worth $3,552,000 after purchasing an additional 357,171 shares during the last quarter. Institutional investors and hedge funds own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.